Individuals with the CYP2C19*17 polymorphism had a higher risk of ischemic events following endovascular treatment compared to those with CYP2C19*1/*1 (32.1% vs 11.4%; OR 3.7; 95% CI 1.1-12.6; P=.04).
Observational (n=108)
Does the CYP2C19*17 genotype increase the risk of ischemic events in patients undergoing cerebral endovascular therapy?
The CYP2C19*17 genotype may be associated with an increased risk of ischemic events following cerebral endovascular treatment, independent of clopidogrel responsiveness.
Odds Ratio: 3.7 (95% CI 1.1–12.6)
Absolute Event Rate: 32.1% vs 11.4%
p-value: p=.04
BACKGROUND AND PURPOSE: Differing responses to clopidogrel following endovascular treatment of cerebrovascular diseases may increase the risk of vascular complications. CYP2C19 gene polymorphisms influence clopidogrel activity. We aimed to study the clinical impact of CYP2C19 gene polymorphisms in patients undergoing endovascular treatment. MATERIALS AND METHODS: This was a prospective, longitudinal, observational study. Information on demographics and cerebrovascular status was collected as baseline. Clopidogrel response was tested by the VerifyNow P2Y12 assay. CYP2C19 genotyping was undertaken by polymerase chain reaction-restriction fragment length polymorphism. Three-month follow-up data included vascular complications, mortality, and modified Rankin Scale score. Associations were investigated among CYP2C19 genotypes, clopidogrel responsiveness, and clinical outcomes. RESULTS: One hundred and eight participants were included. Median age was 56 years (interquartile range, 48.8-65.0 years), and 35 (32.4%) were male. Forty-four participants were classified into group 1 (homozygous CYP2C19*1/*1); 31, into group 2 (25 with CYP2C19*1/*2, two with CYP2C19*1/*3, three with CYP2C19*3/*3, one with CYP2C19*2/*3); 28, into group 3 (24 with CYP2C19*1/*17, four with CYP2C19*17/*17); and 5, into group 4 (CYP2C19*2/*17). A significantly higher proportion of participants in group 3 experienced ischemic events (9 of 28, 32.1%) compared with group 1 (5 of 44, 11.4%; P = .04; odds ratio, 3.7; 95% confidence interval, 1.1-12.6). There was no significant difference in clopidogrel response among the 4 genotype groups. CONCLUSIONS: Individuals with CYP2C19*17 may have increased risk of ischemic events following endovascular treatment, independent of clopidogrel responsiveness. Larger studies are required to confirm the influence of CYP2C19*17 on clinical outcomes and to understand the mechanisms for increased ischemic events.
Lin et al. (Thu,) conducted a observational in Cerebrovascular diseases undergoing endovascular treatment (n=108). CYP2C19*17 polymorphism vs. Homozygous CYP2C19*1/*1 was evaluated on Ischemic events (OR 3.7, 95% CI 1.1-12.6, p=.04). Individuals with the CYP2C19*17 polymorphism had a higher risk of ischemic events following endovascular treatment compared to those with CYP2C19*1/*1 (32.1% vs 11.4%; OR 3.7; 95% CI 1.1-12.6; P=.04).